A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma by Daniel S. Alicea, MS, Bijal Amin, MD, Beth N. McLellan, MD

Subjects: Get full text

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment incl... by Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji

Subjects: Get full text

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma by Maki Todo, Yodo Gatate, Shintaro Nakano, Go Kaneko, Masayuki Hagiwara, Takayuki Takahashi, Yuta Umezawa, Genji Ueda, Shiho Ishikawa, Yoshinori Makino, Masafumi Oyama, Suguru Shirotake

Subjects: “…Nivolumab and ipilimumab…”
Get full text

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer by Yat-Fung Chow, Hou-Hsuan Cheng, Ming-Huang Chen

Subjects: Get full text

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors by Philippe Rochigneux, Philippe Rochigneux, Alexandre Bertucci, Elika Loir, Alexia Mattei, Danielle Robert, Michael Dassa, Brice Chanez, Mikael Ebbo, Lea Gaigne, Anne Sophie Chretien, Giovanni Corazza, Giovanni Corazza, Nicolas Schleinitz

Subjects: Get full text

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE by N. V. Zhukova, R. V. Orlova, N. Yu. Antimonik, S. I. Kutukova, N. P. Belyak, N. V. Popova, S. P. Erdniev

Subjects: Get full text

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops by Ayaka Kawaguchi, Hayato Tanaka, Hitoshi Tabuchi, Kei Nakai, Atsuki Fukushima

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text